Given a notoriously poor local control in vulvar malignant melanoma (VMM) with recurrence rates of 30-50% vs nearly 3% in cutaneous melanomas, researchers analyzed clinicopathologic characteristics of women suffering from VMM (n=37), following reviewing three decades of clinical follow up data in their institutional databases.
Scientific Publications
Frontline BRAF testing–guided treatment for advanced melanoma in the era of immunotherapies: A cost-utility analysis based on long-term survival data
Since the effectiveness of immune checkpoint inhibitors (ICIs) and BRAF and MEK inhibitors have improved advanced melanoma recovery, researchers conducted the study for comparing the cost-utility of these novel agents and their combinations with or without BRAF gene testing guidance for treating newly diagnosed advanced melanoma with unknown BRAF status.
Comorbidity burden on receipt of adjuvant immunotherapy and survival in patients with stage III melanoma: an analysis of the National Cancer Database
Researchers used the National Cancer Database to explore the connection between comorbidity burden, receipt of adjuvant immunotherapy, and survival in patients with stage III melanoma.
Immunotherapy in sinonasal melanoma: treatment patterns and outcomes compared to cutaneous melanoma
In this cohort study, researchers sought to assess whether immunotherapy was correlated with improved survival in sinonasal melanoma (SNM) and to compare the impact of immunotherapy in metastatic sinonasal and cutaneous melanoma.